m 6 A Reader YTHDF1‐Targeting Engineered Small Extracellular Vesicles for Gastric Cancer Therapy via Epigenetic and Immune Regulation (Adv. Mater. 8/2023)

Engineered Extracellular Vesicles In article number 2204910, Jia Yu, Yanlian Yang, Ling Zhu, and co-workers report an extracellular-vesicle-based nanodrug for the targeting delivery of short interfering RNA (siRNA) against N6-methyladenosine (m6A) reader YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) for the epigenetic and immune regulation of gastric cancer. This versatile nanoplatform provides an efficient and low toxic strategy to inhibit epigenetic regulators and holds great potential in promoting immunotherapy.